DesignMedix
DesignMedix develops drugs to treat diseases caused by drug-resistant pathogens.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | $650k | Series B | |
| Total Funding | 000k | ||
Related Content
DesignMedix, Inc. specializes in developing innovative drugs to combat drug resistance, utilizing a unique platform that rapidly synthesizes novel compounds. The company serves small to medium-sized pharmaceutical firms and operates within the biotechnology and pharmaceutical markets. DesignMedix's business model focuses on creating new drugs by linking a chemical moiety from a resistance reversal agent to an existing drug, thereby overcoming resistance and enhancing efficacy. Revenue is generated through partnerships, licensing agreements, and direct sales of their proprietary compounds. The company is based in Portland, Oregon, and aims to improve global health through disruptive pharmaceutical solutions.
Keywords: drug resistance, novel compounds, pharmaceutical, biotechnology, rapid synthesis, resistance reversal, drug development, Portland, partnerships, licensing.